Editorial: Genotype-phenotype map and molecular networks: A promising solution in overcoming colorectal cancer resistance to targeted treatment

Expert Review of Molecular Diagnostics

Volumn 10, Issue 5, 2010, Pages 541-545

  Roukos, Dimitrios H ^a   Katsios, Christos ^a   Liakakos, Theodore ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DNA SEQUENCE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; EDITORIAL; GENE MAPPING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; GENOMICS; GENOTYPE; METHODOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENOMICS; GENOTYPE; HUMANS; PHENOTYPE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77954697543     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.49     Document Type: Editorial

References (36)

1. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 359(6392), 235-237 (1992).
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
3. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008).
4. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
5. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
6. Bergh J. Quo vadis with targeted drugs in the 21st century? J. Clin. Oncol. 27(1), 2-5 (2009).
7. Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn. 9(3), 217-221 (2009).
8. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J. Clin. Oncol. 23(25), 5856-5858 (2005).
9. Peterson RT. Drug discovery: propping up a destructive regime. Nature 461(7264), 599-600 (2009).
10. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264), 614-620 (2009).
11. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
12. Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27(6), 872-877 (2009).
13. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
14. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
15. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
16. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
17. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
18. Bastiaens P. Systems biology: when it is time to die. Nature 459(7245), 334-335 (2009).
19. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther. 9(10), 1413-1416 (2009).
20. The human genome at ten. Nature 464(7289), 649-650 (2010).
21. Check Hayden E. Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010).
22. Human genome at ten: the sequence explosion. Nature 464(7289), 670-671 (2010).
23. Ledford H. Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010).
24. Collins F. Has the revolution arrived? Nature 464(7289), 674-675 (2010).
25. Venter JC. Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
26. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
27. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
28. Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010).
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
30. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002).
31. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
32. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
33. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
34. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
35. Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
36. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).